Your shopping cart is currently empty

HMGB1-IN-1 (compound 6) exhibits potent inhibition of NO production in RAW264.7 cells, with an IC50 of 15.9 ± 0.6 μM, and effectively disrupts the HMGB1/NF-κB/NLRP3 signaling pathway, demonstrating promising anti-inflammatory and anti-sepsis properties, particularly in the context of renal injury [1].
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | HMGB1-IN-1 (compound 6) exhibits potent inhibition of NO production in RAW264.7 cells, with an IC50 of 15.9 ± 0.6 μM, and effectively disrupts the HMGB1/NF-κB/NLRP3 signaling pathway, demonstrating promising anti-inflammatory and anti-sepsis properties, particularly in the context of renal injury [1]. |
| In vitro | HMGB1-IN-1 (compound 6) (0-30 μM, 0-48 h) reduces IL-1β and TNF-α levels in RAW264.7 and HK-2 cells and demonstrates dose-dependent downregulation of NLRP3, P-NF-κB p65, and HMGB1 in activated HK-2 cells [1]. |
| In vivo | HMGB1-IN-1 (compound 6), when administered intraperitoneally at doses ranging from 15 to 30 mg/kg, demonstrates potent anti-inflammatory activity [1]. |
| Molecular Weight | 1042.22 |
| Formula | C57H75N3O15 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.